BNFC July 2024 Update

This update contains 7 significant changes, 1 new preparation, and 1 deleted monograph.

Significant Changes:

• Borderline substances: products suitable for additional energy, protein, or fibre requirements have been moved to a new section called Energy, protein, and fibre fortifiers.
• Co-codamol: update to dose expression.
• Combined hormonal contraceptives: update to breast-feeding advice (see example in ethinylestradiol with norethisterone).
• Dabigatran etexilate: Direct-acting oral anticoagulants (DOACs): paediatric formulations [MHRA/CHM advice].
• Ear: updated guidance for the removal of ear wax.
• Intra-uterine contraceptive devices (copper): name change of Novaplus T 380® Ag to Eurogine T 380® Ag, and name change of Novaplus T 380® Cu to Eurogine T 380® Cu.
• Montelukast: reminder of the risk of neuropsychiatric reactions [MHRA/CHM advice].

New preparations:

• Pradaxa® oral granules [dabigatran etexilate].

Deleted Monographs:

• Soybean oil.